Global Systemic Sclerosis Market is estimated to be US$ 3.6 billion by 2030 with a CAGR of 5.30% dur (Business Opportunities - Marketing & Sales)

USAOnlineClassifieds > Business Opportunities > Marketing & Sales

Item ID 1559185 in Category: Business Opportunities - Marketing & Sales

Global Systemic Sclerosis Market is estimated to be US$ 3.6 billion by 2030 with a CAGR of 5.30% dur


Global Systemic Sclerosis Market accounted for US$ 2.2 billion in 2020 and is estimated to be US$ 3.6 billion by 2030 and is anticipated to register a CAGR of 5.30%. Systemic sclerosis, also known as systemic fibrosis, is an autoimmune rheumatic illness marked by excessive collagen formation and buildup in the skin and internal organs, as well as injury to tiny arteries. Based on the level of skin involvement, there are two broad subtypes of systemic sclerosis: limited and diffuse. With or without facial involvement, the limited form affects areas below, but not above, the elbows and knees. The skin above the elbows and knees is also affected by the diffuse type, which can spread to the torso.

The report " Global Systemic Sclerosis Market, By Drug Class (Immunosuppressors, PDE-5 Inhibitors, Endothelin Receptor Antagonist, Prostacyclin Analogues) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030’’
Key Highlights:

Kadmon Holdings, Inc. acquired Orphan Medication Designation from the US Food and Drug Administration in September 2020 for its innovative drug candidate, belumosudil (KD025), which is designed to treat systemic sclerosis.
Analyst View:

Researchers and sponsors are concentrating their efforts on rapidly generating new prospective candidates. The kind and method of action of these pipeline products varies. For example, Kadmon Holdings, Inc. acquired Orphan Medication Designation from the US Food and Drug Administration in September 2020 for its innovative drug candidate, belumosudil (KD025), which is designed to treat systemic sclerosis. Belumosudil (KD025) is a Rho-associated coiled-coil kinase 2 inhibitor with a dual mode of action that targets both immunological and fibrotic components. It is currently being tested in a phase 2 clinical trial.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Systemic Sclerosis Market, By Drug Class (Immunosuppressors, PDE-5 Inhibitors, Endothelin Receptor Antagonist, Prostacyclin Analogues) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”
To know the upcoming trends and insights prevalent in this market, click the link below:

https://www.prophecymarketinsights.com/market_insight/Global-Systemic-Sclerosis-Market-4775

Related Link: Click here to visit item owner's website (0 hit)

Target State: All States
Target City : All Cities
Last Update : Nov 18, 2021 1:50 AM
Number of Views: 46
Item  Owner  : NileshDM
Contact Email:
Contact Phone: 7775049802

Friendly reminder: Click here to read some tips.
USAOnlineClassifieds > Business Opportunities > Marketing & Sales
 © 2022 USAOnlineClassifieds.com
2022-05-19 (0.401 sec)